Ortho Development Corporation received FDA 510(k) clearance for its Trivicta hip system, which utilizes a triple-taper stem for stability in total hip arthroplasty. The system will be available in the US in the second quarter of 2024. The company’s president and CEO, Brent Bartholomew, highlighted Trivicta’s versatility in addressing a range of patient needs and accommodating different surgical approaches. The system is part of Ortho Development’s primary hip portfolio and aims to provide innovative solutions for patients and surgeons.
Source link
Ortho Development receives FDA 510(k) clearance of hip system with triple-taper stem
